We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Specialized Nuclear Bodies Delay and Promote Repair of DNA Damage

By LabMedica International staff writers
Posted on 14 Mar 2019
Print article
Image: Specialized proteins protect damaged DNA in the cell nucleus (pink shapes) until the damage can be repaired (Photo courtesy of the University of Copenhagen).
Image: Specialized proteins protect damaged DNA in the cell nucleus (pink shapes) until the damage can be repaired (Photo courtesy of the University of Copenhagen).
A molecular mechanism that helps minimize the impact of natural DNA errors, which occur during the process of cell division and replication, was identified and characterized in cultures of human cells.

Failure to complete DNA replication is a by-product of genome doubling in almost every cell cycle. During mitosis, under-replicated DNA (UR-DNA) is converted into DNA lesions, which are inherited by daughter cells and sequestered in 53BP1 nuclear bodies (53BP1-NBs).

The fate of DNA with unresolved replication intermediates is not known. Previous studies showed that mild replication stress increased the frequency of chromosomal lesions that were transmitted to daughter cells. Throughout G1, these lesions were sequestered in nuclear compartments marked by p53-binding protein 1 (53BP1) and other chromatin-associated genome caretakers. The number of such 53BP1 nuclear bodies increased after genetic ablation of BLM, a DNA helicase associated with dissolution of entangled DNA. Conversely, 53BP1 nuclear bodies were partially suppressed by knocking down SMC2, a condensin subunit required for mechanical stability of mitotic chromosomes. In addition, 53BP1 nuclear bodies protected chromosomal fragile sites sequestered in these compartments against erosion.

In the current study, which was published in the February 25, 2019, online edition of the journal Nature Cell Biology, investigators at the University of Copenhagen (Denmark) showed that the formation of 53BP1-NBs interrupted the chain of repetitive damage intrinsically embedded in UR-DNA. This result was obtained by labeling 53BP1-NBs in living human cells using fluorescent dyes and then following them under a microscope over several successive generations. Using this method, the investigators traced the fate of inherited DNA damage directly from the time of generation in mother cells to their final destiny in daughter cells.

The investigators found that unlike clastogen-induced 53BP1 foci that were repaired throughout interphase, 53BP1-NBs restrained replication of the embedded genomic loci until late S phase, thus enabling the dedicated RAD52-mediated repair of UR-DNA lesions. A clastogen is a mutagenic agent giving rise to or inducing disruption or breakages of chromosomes, leading to sections of the chromosome being deleted, added, or rearranged. RAD52 is a protein that plays a central role in genetic recombination and DNA repair by promoting the annealing of complementary single-stranded DNA and by stimulation of the RAD51 recombinase.

The absence or malfunction of 53BP1-NBs caused premature replication of the affected loci, accompanied by genotoxic RAD51-mediated recombination (a genotoxic agent is a chemical or another agent that damages cellular DNA, resulting in mutations or cancer). Thus, by adjusting replication timing and repair pathway choice at under-replicated loci, 53BP1-NBs enabled the completion of genome duplication of inherited UR-DNA and prevented the conversion of under-replications into genome instability.

"53BP1 nuclear bodies delay cell division in daughter cells in order to reach the only remaining time in their lifecycle when they can mend DNA lesions that their mother caused but could not fix. This second chance is vital because it is also the last one. We have predicted and then experimentally documented that a failure of this second chance converts the initially curable DNA damage to one that can no longer be fixed. Accumulation of such mishaps could lead to disease, including cancer", said senior author Dr. Kai John Neelsen, assistant professor of protein research at the University of Copenhagen.

Related Links:
University of Copenhagen

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.